Oxygen Biotherapeutics, Inc. Sets FDA Meeting Date for Proposed Phase IIb Oxycyte Clinical Trial

COSTA MESA, Calif.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) today announced that the company is tentatively scheduled to meet with the U.S. Food and Drug Administration (FDA) during the week of Oct. 20, 2008 to discuss any remaining issues that the agency has about the use of Oxycyte® in a proposed Phase IIb clinical trial in Traumatic Brain Injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier. The meeting date and time are subject to final confirmation by the agency.